Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY

Background EMPA–KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan. Methods Eligibility required an estimated glomerular filtration rate (eGFR) of ≥ 20 

Saved in:
Bibliographic Details
Published in:Clinical and experimental nephrology 2024-06, Vol.28 (6), p.588-595
Main Authors: Nangaku, Masaomi, Herrington, William G., Goto, Shinya, Maruyama, Shoichi, Kashihara, Naoki, Ueki, Kohjiro, Wada, Jun, Watada, Hirotaka, Nakashima, Eitaro, Lee, Ryonfa, Massey, Dan, Mayne, Kaitlin J., Tomita, Aiko, Haynes, Richard, Hauske, Sibylle J., Kadowaki, Takashi
Format: Article
Language:English
Subjects:
Creatinine
Death
Diabetes mellitus
End-stage renal disease
Epidermal growth factor receptors
Glomerular filtration rate
Kidney diseases
Medicine
Medicine & Public Health
Nephrology
Placebos
Rapid Communication
Urology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background EMPA–KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan. Methods Eligibility required an estimated glomerular filtration rate (eGFR) of ≥ 20 
ISSN:1342-1751
1437-7799
1437-7799
DOI:10.1007/s10157-024-02489-4